2018 American Transplant Congress
Evaluation of Tacrolimus Extended-Release in African American Renal Transplant Recipients
University of Maryland, Baltimore.
Purpose: Limited data exists to guide appropriate dosing strategies for novel tacrolimus formulations, such as tacrolimus XL (Astagraf XL). This is especially true in the…2018 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients- 3 Years Follow-Up
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2018 American Transplant Congress
Clinical Significance of Tacrolimus Trough Level at the Early Period after Kidney Transplantation
Background:The stable immunosuppressant level at the early period after kidney transplantation (KT) is one of the most important factors to decide the prognosis of KT.…2018 American Transplant Congress
Tacrolimus and Isavuconazole Therapy: What about the Drug Interaction?
1Henry Ford Hospital, Detroit; 2Wayne State University, Detroit, MI.
Introduction:Isavuconazole (ISV) is a triazole antifungal that is often utilized in solid organ transplant recipients (SOTR) for the treatment of invasive aspergillosis and mucormycosis. Isavuconazole…2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…2018 American Transplant Congress
Prevalence and Impact of CYP3A5 Genomic Variances on Clinical Outcomes among African-American Kidney Transplant Recipients
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC.
Introduction: Kidney transplantation in African American (AA) recipients continues to demonstrate inferior outcomes when compared with other race/ethnicities. Contributing factors encompass differences in pharmacogenomics, and…2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…2018 American Transplant Congress
Tacrolimus Exposure in Human Proximal Tubule Cells Results in Differentially Increased CTGF Expression in Relation to Pharmacogenetic Variants of CYP3A5 and ABCB1
AIM: Clinical studies have demonstrated the importance of genetic variation for tacrolimus disposition and suggested a role in the development of renal fibrosis associated with…2018 American Transplant Congress
De Novo Use of Extended Released Tacrolimus (Meltdose, EnvasusR)) after OLT – Does the Colonic Resorption Influences the Outcome?
Department of Transplantation, Medical University of Vienna, Vienna, Austria.
Introduction: Immunosuppression after OLT has reached a quite high standard with an excellent evidence base. However, there is still a lack of data for the…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »